Sector News

Abbott, Mylan back generics deal, tweak terms after tax rule change

October 22, 2014
Life sciences
(Reuters) – Abbott Laboratories and Mylan Inc on Wednesday said they would go ahead with their $5.3 billion deal in which Mylan will buy part of Abbott’s overseas generics business and set up headquarters in the Netherlands, but they tweaked the terms of the transaction.
 
The move comes after the U.S. Treasury on Sept. 22 made changes to the corporate tax rules that govern such “inversion” merger deals, in which companies move their operations to countries with lower taxes than in the United States. The new rules raise the bar for this tax treatment and also make it harder to reap other tax benefits of an inversion.
 
About ten U.S. companies had deals in the works when the Treasury changed the rules. Some, including Salix Pharmaceuticals and former Abbott business Abbvie, pulled out of their own inversion-based deals, while others decided to go forward with their deals.
 
Investors and analysts were not certain where Abbott and Mylan would fall.
 
“The positive takeaway is that Abbott still plans to close its deal with Mylan in the first quarter of 2015, despite the pressure on inversions from the U.S. Treasury, and some walking away by other companies from inversions,” said Jeff Windau, an analyst with Edward Jones. “The (tax law) changes from Treasury are making people re-look at deal terms, and deals are not as favorable now. That’s what happened here, there had to be some tweaks.”
 
Abbott plans to sell to Mylan its generics business in developed markets outside the United States. It plans to keep its generic brands in fast-growing emerging markets.
 
Mylan said that the terms of the deal were changed to include better pricing terms for Mylan at Abbott units that will manufacture and supply products for Mylan. It also said that Mylan will issue 110 million shares in the newly formed company to Abbott, 5 million more than the original terms dictated.
 
Mylan shareholders will own 78 percent of the company and Abbott will own 22 percent of the new company. Mylan said the deal would be accretive.
 
Abbott has said it plans to quickly sell the shares after the closing of the deal. (Reportingby Caroline Humer and Ransdell Pierson; Editing by Chizu Nomiyama)

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).